Literature DB >> 17902149

Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.

Ruben Boogaard1, Johan C de Jongste, Peter J F M Merkus.   

Abstract

Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17902149     DOI: 10.1002/ppul.20693

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

Review 1.  Airway mucus function and dysfunction.

Authors:  John V Fahy; Burton F Dickey
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

2.  How cations can assist DNase I in DNA binding and hydrolysis.

Authors:  Marc Guéroult; Daniel Picot; Joséphine Abi-Ghanem; Brigitte Hartmann; Marc Baaden
Journal:  PLoS Comput Biol       Date:  2010-11-18       Impact factor: 4.475

3.  Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome.

Authors:  Philipp Eickhoff; Tamas Fazekas; Hans Wank; Ulrike Kastner
Journal:  Wien Klin Wochenschr       Date:  2014-06-05       Impact factor: 1.704

Review 4.  Clinical review: airway hygiene in the intensive care unit.

Authors:  Sanja Jelic; Jennifer A Cunningham; Phillip Factor
Journal:  Crit Care       Date:  2008-03-31       Impact factor: 9.097

5.  SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis.

Authors:  Mark L Everard; Daniel Hind; Kelechi Ugonna; Jennifer Freeman; Mike Bradburn; Cindy L Cooper; Elizabeth Cross; Chin Maguire; Hannah Cantrill; John Alexander; Paul S McNamara
Journal:  Thorax       Date:  2014-12       Impact factor: 9.139

Review 6.  Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey.

Authors:  Bibiche den Hollander; Rosalie S N Linssen; Bart Cortjens; Fardi S van Etten-Jamaludin; Job B M van Woensel; Reinout A Bem
Journal:  Eur J Hosp Pharm       Date:  2020-10-29

7.  Genetics, diagnosis, and future treatment strategies for primary ciliary dyskinesia.

Authors:  M Leigh Anne Daniels; Peadar G Noone
Journal:  Expert Opin Orphan Drugs       Date:  2014-11-29       Impact factor: 0.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.